Q-omics provides the consensus-scored RASA4CP profile across patient tissues and cancer cell-line models. RASA4CP expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RASA4CP is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, RASA4CP RNA expression shows 16,231 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where RASA4CP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RASA4CP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RASA4CP survival associations across molecular data types. RASA4CP RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RASA4CP RNA expression–survival associations across cancer types. High RASA4CP expression shows unfavorable associations in ACC, LAML and SKCM, but favorable associations in HNSC, PAAD and UVM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for RASA4CP RNA expression.
This table summarizes RASA4CP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RASA4CP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RASA4CP shows lower tumor expression in HNSC, UCEC, COAD, KIRP and KIRC and higher tumor expression in LIHC. The HNSC box plot shows higher RASA4CP RNA expression in normal versus tumor tissue (log2 FC = −0.389, t-test p < 0.001).
This table shows molecular features associated with RASA4CP in patient tissues and cancer cell lines. In patient samples, RASA4CP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RASA4CP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
